SATELLOS Bioscience Announces 2023 Q3 Financial Results and Operational Highlights
Company disclosed drug target for Duchenne program; remains on track to initiate clinical trials mid-2024
Company disclosed drug target for Duchenne program; remains on track to initiate clinical trials mid-2024
TORONTO, November 20, 2023 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB:
The drug target for the Duchenne program is AAK1, a protein kinase in the Notch
TORONTO, November 2, 2023 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB:
TORONTO, September 20, 2023 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB:
TORONTO, September 7, 2023 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB:
Elizabeth Williams, CPA, CA, joins as CFO, bringing extensive expertise leading corporate finance and strategy
$48.7 million in cash and cash equivalents at June 30, 2023, providing expected runway to
Company also recently received Rare Pediatric Disease Designation from the FDA for SAT-3153 for the
TORONTO, June 30, 2023 – Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Company”), a